...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >An n-of-1 Trial Service in Clinical Practice: Testing the Effectiveness of Liuwei Dihuang Decoction for Kidney-Yin Deficiency Syndrome
【24h】

An n-of-1 Trial Service in Clinical Practice: Testing the Effectiveness of Liuwei Dihuang Decoction for Kidney-Yin Deficiency Syndrome

机译：临床实践中的一项N-of-1试验服务：测试刘伟副肾脏肾脏缺乏综合征的刘伟Dihuang汤的有效性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective. To describe the clinical use of n-of-1 RCTs for kidney-Yin deficiency syndrome that is a traditional Chinese medicine syndrome in publicly clinical practice in China.Methods. Our study included patients with kidney-Yin deficiency syndrome, using a within-patient, randomized, double-blind, crossover comparison of Liuwei Dihuang decoction versus placebo.Outcome Measures. Primary outcome measures included number of individual completion rates, response rate, and post-n-of-1 RCTs decisions. Secondary measures were the whole group score of individual Likert scale, SF-36 questionnaire.Results. Fifty patients were recruited and 3 were not completed. Forty-seven patients completed 3 pairs of periods, 3 (6.38%) were responders, 28 (59.57%) were nonresponders, and 16 (34.05%) were possible responders. Doctors and patients used the trial results to making decision. Three responders stayed on the medication management, 28 nonresponders ceased the LDD, 7 patients of the 16 possible responders could not give clear decision, and the others kept the same medication station. Among the whole group, neither the individual Likert score nor the SF-36 showed any statistical differences between LDD and placebo.Discussion. More attention should be paid to choose experienced TCM doctor as investigator and keep the simulant same with test medication in n-of-1 RCTs of TCM and sufficiently biological half-life period of Chinese medicine compound.
机译：客观的。描述N-1次RCT对肾阴缺乏综合征的临床应用，即在中国公开临床实践中的中医综合症。方法。我们的研究包括肾阴缺乏症患者，使用内部患者，随机，双盲，脉络Dihuang汤的交叉比较与安慰剂。作用措施。主要成果措施包括个人完成率，响应率和1后1个RCT的次数。次要措施是个别李克特规模的整体群体得分，SF-36问卷。结果。招募了五十名患者，3名没有完成。四十七名患者完成了3对时期，3（6.38％）是受访者，28例（59.57％）无回应者，16名（34.05％）是可能的响应者。医生和患者使用审判结果做出决定。三个响应者留在药物管理中，28名无回复者停止了LDD，7名16个可能的响应者的患者不能发出明确的决定，而其他患者则保持相同的药物站。在整个组中，个人李克特得分和SF-36都没有显示出LDD和安慰剂之间的任何统计差异。应更多地关注以选择有经验的中医医生作为调查员，并使模拟剂与测试药物相同，在中医的N-1次RCT中和中药化合物的充分生物半衰期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号